| Identification | More | [Name]
Etamsylate | [CAS]
2624-44-4 | [Synonyms]
ETAMSYLATE
ETHAMSYLATE
1-hydroxy-4-oxo-2,5-cyclohexadiene-1-sulfonicacidcompd.withdiethylamine
2,5-dihydroxy-benzenesulfonicacicompd.withdiethylamine
2,5-dihydroxy-benzenesulfonicacicompd.withn-ethylethanamine(1:1)
2,5-dihydroxybenzenesulfonicacidcompd.withn-ethylethanamine
2,5-DihydroxybenzenesulfonicacidcompdwithN-ethylethanamine
aglumin
altodor
ciclonamina
cyclonamine
dicynene
dicynone
diethylammonium2,5-dihydroxybenzenesulfonate
diethylammoniumcyclohexadien-4-ol-1-one-4-sulfonate
diidroxi-1,4-benzenesulfonato-3-di-etilammonium
e141
eselin
md141
diethylammonium 2,5-dihydroxybenzenesulphonate | [EINECS(EC#)]
220-090-7 | [Molecular Formula]
C10H17NO5S | [MDL Number]
MFCD00867499 | [Molecular Weight]
263.31 | [MOL File]
2624-44-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
125° | [density ]
1.3441 (rough estimate) | [refractive index ]
1.5060 (estimate) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Very soluble in water, freely soluble in methanol, soluble in anhydrous ethanol, practically insoluble in methylene chloride. | [form ]
neat | [color ]
White to Pale Red | [Merck ]
14,3722 | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3 | [InChIKey]
HBGOLJKPSFNJSD-UHFFFAOYSA-N | [SMILES]
C1(S(=O)(=O)O)=CC(=CC=C1O)O.N(CC)CC | [CAS DataBase Reference]
2624-44-4(CAS DataBase Reference) | [EPA Substance Registry System]
2624-44-4(EPA Substance) |
| Safety Data | Back Directory | [RTECS ]
DB6145000 | [HS Code ]
2921.19.6190 | [HazardClass ]
IRRITANT | [Toxicity]
LD50 i.v. in mice, rats: 800, 1350 mg/kg (Esteve) |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Haemostatic / Anti Coagulant | [Uses]
Hemostatic;prostaglandin synthesis inhibitor | [Definition]
ChEBI: Etamsylate is a sulfonic acid derivative and an organosulfur compound. | [Biological Activity]
Etamsylate is a haemostatic agent th at is used for the management of blood loss. Apparently etamsylate increases capillary wall resistance and platelet adhesives by inhibition of the biosynthesis of prostaglandins causing platelet disaggregation in a presence of vascular wound. Recent studies suggest th at etamsylate antagonizes anti-coagulant activity of heparin. | [Mechanism of action]
Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
| [Clinical Use]
Short-term treatment of blood loss in menorrhagiaProphylaxis of surgical bleeding (unlicensed) | [Side effects]
Significant: Hypotension (parenteral). Rarely, severe hypersensitivity reaction, including anaphylaxis.
Blood and lymphatic system disorders: Parenteral: Rarely, neutropenia, agranulocytosis, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort.
General disorders and administration site conditions: Asthenia (parenteral). Rarely, fever.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Rarely, thromboembolism (parenteral).
| [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Etamsylate is excreted unchanged, mainly in the urine. |
|
|